Source: Υπουργείο Υγείας (CY) Revision Year: 2018 Publisher: Remedica Ltd., Aharnon Str., Limassol Industrial Estate, 3056 Limassol, Cyprus
In combination with other active anti-tuberculosis drugs in the treatment of all forms of tuberculosis, including fresh, advanced, chronic and drug-resistant cases. Rifaren is also effective against most atypical strains of Mycobacteria.
In combination with at least one other active anti-leprosy drug in the management of multibacillary and paucibacillary leprosy to effect conversion of the infectious state to a non-infectious state.
In the treatment of Brucellosis, Legionnaires Disease, and serious staphylococcal infections. To prevent emergence of resistant strains of the infecting organisms, Rifaren should be used in combination with another antibiotic appropriate for the infection.
For the treatment of asymptomatic carriers of N. meningitidis to eliminate meningococci from the nasopharynx.
For the treatment of asymptomatic carriers of H. influenzae and as chemoprophylaxis of exposed children, 4 years of age or younger.
For oral use.
The daily dose of Rifaren, calculated from the patient’s body weight, should preferably be taken at least 30 minutes before a meal or 2 hours after a meal to ensure rapid and complete absorption.
Rifaren should be given with other effective anti-tuberculosis drugs to prevent the possible emergence of rifampicin-resistant strains of Mycobacteria.
Adults: The recommended single daily dose in tuberculosis is 8-12 mg/kg.
Usual Daily dose: Patients weighing less than 50 kg – 450 mg. Patients weighing 50 kg or more – 600 mg.
Children: In children, oral doses of 10-20 mg/kg body weight daily are recommended, although a total daily dose should not usually exceed 600 mg.
600 mg doses of rifampicin should be given once per month. Alternatively, a daily regimen may be used. The recommended single daily dose is 10 mg/kg.
Usual daily dose: Patients weighing less than 50 kg – 450 mg. Patients weighing 50 kg or more – 600 mg.
In the treatment of leprosy, rifampicin should always be used in conjunction with at least one other antileprosy drug.
Adults: The recommended daily dose is 600-1200 mg given in 2 to 4 divided doses, together with another appropriate antibiotic to prevent the emergence of resistant strains of the infecting organisms.
Adults: 600 mg twice daily for 2 days.
Children (1 – 12 years): 10 mg/kg twice daily for 2 days.
Children (3 months – 1 year): 5 mg/kg twice daily for 2 days.
Adults and children: For members of households exposed to H. influenzae B disease when the household contains a child 4 years of age or younger, it is recommended that all members (including the child) receive rifampicin 20 mg/kg once daily (maximum daily dose 600 mg) for 4 days.
Index cases should be treated prior to discharge from hospital.
Neonates (1 month): 10 mg/kg daily for 4 days.
A daily dose of 8 mg/kg should not be exceeded in patients with impaired liver function.
In elderly patients, the renal excretion of rifampicin is decreased proportionally with physiological decrease of renal function; due to compensatory increase of liver excretion, the terminal half-life in serum is similar to that of younger patients. However, as increased blood levels have been noted in one study of rifampicin in elderly patients, caution should be exercised in using rifampicin in such patients, especially if there is evidence of impaired liver function.
Nausea, vomiting, abdominal pain, pruritus, headache and increasing lethargy will probably occur within a short time after acute ingestion; unconsciousness may occur when there is severe hepatic disease. Transient increases in liver enzymes and/or bilirubin may occur. Brownish-red or orange colouration of the skin, urine, sweat, saliva, tears and faeces will occur, and its intensity is proportional to the amount ingested. Facial or periorbital oedema has also been reported in paediatric patients. Hypotension, sinus tachycardia, ventricular arrhythmias, seizures and cardiac arrest were reported in some fatal cases.
The minimum acute lethal or toxic dose is not well established. However, nonfatal acute overdoses in adults have been reported with doses ranging from 9 to 12 g rifampicin. Fatal acute overdoses in adults have been reported with doses ranging from 14-60 g. Alcohol or a history of alcohol abuse was involved in some of the fatal and nonfatal reports.
Nonfatal overdoses in paediatric patients' ages 1 to 4 years old of 100 mg/kg for one to two doses have been reported.
Intensive supportive measures should be instituted and individual symptoms treated as they arise. Since nausea and vomiting are likely to be present, gastric lavage is probably preferable to induction of emesis. Following evacuation of the gastric contents, the instillation of activated charcoal slurry into the stomach may help absorb any remaining drug from the gastrointestinal tract. Antiemetic medication may be required to control severe nausea and vomiting. Active diuresis (with measured intake and output) will help promote excretion of the drug. Haemodialysis may be of value in some patients.
5 years.
Store below 25°C. Protect from light and moisture.
Rifaren 150 mg capsules:
PVC/Aluminium blisters. Pack-sizes of 20, 100 and 1000 capsules.
PP containers with PE closure. Pack-sizes of 100 and 1000 capsules.
Rifaren 300 mg capsules:
PVC/Aluminium blisters. Pack-sizes of 20, 100 and 1000 capsules.
PP containers with PE closure. Pack-sizes of 100 and 1000 capsules.
Not all pack-sizes may be marketed.
No special requirements.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
